Interní Med. 2009; 11(12): 569-572

Hormonal contraception - news, benefits, risks, new medication

MUDr.Hana Hrušková
Gynekologicko-porodnická klinika VFN a 1. LF UK, Praha

The article overviews hormonal contraception remedies that are currently available on the Czech market and reviews their counter-indications,

non-contraception benefits and risks.

Keywords: hormonal contraception, ethinyl estradiol, estradiol valerat, progestins

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrušková H. Hormonal contraception - news, benefits, risks, new medication. Interní Med. 2009;11(12):569-572.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Szarewská A, Guillebaud J. Antikoncepce. Praha: Victoria Publishing 1996; 218 s.
    2. Uzel R. 4000 let antikoncepce. Nová tiskárna Pelhřimov, Praha 2003; 65 s.
    3. Fait T. Antikoncepce. Jessenius Maxdorf, Praha 2008; 86 s.
    4. Čepický P, Cibula D, Dvořák K, et al. Doporučení k předpisu kombinované hormonální antikoncepce. Česká gynekologie 2000; 65 (4): 279-282, aktualizace 2005. Go to PubMed...
    5. Collaborative Group on Epidemiological Studies of Ovarian cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 2008; 371 (9609): 303-314. Go to original source... Go to PubMed...
    6. Hannaford PC. Cancer risk among user sof oral contraceptives: kohort data from the Royal College of general Practitioners´oral contraception study. BMJ 2007; 335: 651. Go to original source... Go to PubMed...
    7. Jick H. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000; 321: 1190-1995. Go to original source... Go to PubMed...
    8. Parkin l, Skegg DCG, Wilson M, et al. Oral Contraceptives and fatal pulmonary embolism. Lancet 2000; 355: 2133-2134. Go to original source... Go to PubMed...
    9. Ústav zdravotnických informací a statistiky - www.uzis.cz.
    10. Dulíček P, Košťál M. Hormonální antikoncepce a trombembolická nemoc. Speciální vydání Gynekologie po promoci, Praha 2002; 11 s.
    11. Lewis MA, Heinemann LAJ, Spitzer WO, et al. The use of oral contraceptives and the occurence of acute myocardial infarction in youg women. Results from Transnational Study on Oral contraceptives and the Health of Young Women. Contraception 1997; 56: 129-140. Go to original source... Go to PubMed...
    12. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to afficacy, cycle control and tolerance. Contraception 1997; 55: 131-137. Go to original source... Go to PubMed...
    13. Seidlová D. Kontracepce pro praxi. Praha Jessenius Maxdorf, 1997; 148 s.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.